News

HPV Transcriptome as a Game-Changing Biomarker for Detection, Genotyping, and Monitoring of HPV-Associated Cervical High-Grade Cytology LUXEMBOURG, LUXEMBOURG, April 22, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (ABL), a diagnostics company, headquartered in Luxembourg, is ple…

ABL and affiliates plan to start the production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics ABL Diagnostics SA (EPA:ABLD) LUXEMBOURG VILLE, LUXEMBOURG, February 3, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (A…

22.11.2023 at 4:30 to 6:00 p.m. (CET) These European guidelines for the preoperative measurement of liver function were published in June of this year. This represents an important milestone for the use of the LiMAx test and underlines its importance for the safety of patients and surgeons. In our w…

PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, and Humedics GmbH, a le…

ABL SA acquires the company Humedics Gmbh to extend the use of a robust, well-known, and CE-marked technology intended to be used for liver function measurement.  Financial terms are not disclosed. Doctor Chalom Sayada, founder of the ABL SA and managing director of the Humedics declared: “We are pr…

On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays an…

Paris, le 31 août 2022, Lors de la réunion du 3 août 2022 et dans le prolongement des communications effectuées à ce sujet, l’assemblée générale des actionnaires de la société ABL Diagnostics (la « Société ») a approuvé le projet de fusion-absorption de la société Advanced Biological Laboratories Fe…

WHO algorithm v2021-06 for Tuberculosis resistance now available!

We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement.

ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”

The UltraGene™ Assay SARS-CoV-2 PrimeChek™ is a CE-IVD marked real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 by their healthcare provider.  

This week we are proud to have two new Distribution Partners on our side : – ELTA 90 Medical Genetics in Georgia – Infotec in Paraguay Both agreements will cover all ABL’s Diagnostics line of products, including the DeepChek® Assays and Softwares.  

Le Conseil d’administration de la société ABL Diagnostics (la « Société »), réuni le 13 juin 2022, a approuvé le projet de fusion-absorption aux termes duquel il est prévu que la Société absorbe la société Advanced Biological Laboratories Fedialis (« ABL France »), chacune des deux sociétés étant co…

We are pleased to announce that we entered into an exclusive distribution agreement 🤝 of ABL’s Diagnostics line of products, including the DeepChek® Assays 🔬and software: – With Retina Pharmaceuticals in Ethiopia; – With Bionova in Bolivia !  

We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked !    

We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information.

ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est…